Neurogene (NASDAQ:NGNE) CFO Sells $25,170.34 in Stock

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic sold 739 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $34.06, for a total value of $25,170.34. Following the sale, the chief financial officer owned 92,901 shares in the company, valued at $3,164,208.06. The trade was a 0.79% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Mikail Cvijic also recently made the following trade(s):

• On Thursday, July 2nd, Christine Mikail Cvijic sold 4,061 shares of Neurogene stock. The stock was sold at an average price of $34.82, for a total value of $141,404.02.
• On Wednesday, May 6th, Christine Mikail Cvijic sold 9,600 shares of Neurogene stock. The stock was sold at an average price of $31.25, for a total value of $300,000.00.

Neurogene Stock Performance

Shares of Neurogene stock opened at $35.34 on Friday. The firm has a market capitalization of $558.37 million, a PE ratio of -7.77 and a beta of 1.68. The business’s 50-day moving average price is $29.39 and its 200-day moving average price is $23.33. Neurogene Inc. has a 12 month low of $15.93 and a 12 month high of $37.27.

Neurogene (NASDAQ:NGNE) last released its earnings results on Tuesday, May 12th. The company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.09). As a group, analysts predict that Neurogene Inc. will post -5.63 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Jennison Associates LLC increased its stake in shares of Neurogene by 35.3% in the fourth quarter. Jennison Associates LLC now owns 533,088 shares of the company’s stock worth $10,982,000 after buying an additional 138,999 shares during the period. ArrowMark Colorado Holdings LLC boosted its position in Neurogene by 1.8% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 595,839 shares of the company’s stock valued at $10,326,000 after buying an additional 10,442 shares during the period. PNC Financial Services Group Inc. grew its holdings in Neurogene by 24.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 5,055 shares of the company’s stock worth $88,000 after acquiring an additional 1,000 shares during the last quarter. Schroder Investment Management Group grew its holdings in Neurogene by 73.3% in the 4th quarter. Schroder Investment Management Group now owns 52,300 shares of the company’s stock worth $1,156,000 after acquiring an additional 22,123 shares during the last quarter. Finally, Raiffeisen Bank International AG grew its holdings in Neurogene by 23.5% in the 4th quarter. Raiffeisen Bank International AG now owns 42,000 shares of the company’s stock worth $929,000 after acquiring an additional 8,000 shares during the last quarter. Institutional investors own 52.37% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Neurogene in a research report on Tuesday, June 9th. Rodman & Renshaw assumed coverage on shares of Neurogene in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $70.00 price target for the company. Canaccord Genuity Group cut their price target on shares of Neurogene to $180.00 and set a “buy” rating for the company in a research report on Monday, April 6th. Finally, UBS Group set a $70.00 price objective on Neurogene in a research note on Wednesday, June 3rd. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $84.83.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.